Liver Cancer in Sub-Saharan Africa
Death rates for Liver Cancer across 48 countries in Sub-Saharan Africa.
| # | Country | Rate |
|---|
Across the 48 countries in Sub-Saharan Africa tracked in this dataset, liver cancer accounts for an average of 2.2% of total deaths. The regional average of 2.2% is roughly in line with the global average of 2.3%, placing Sub-Saharan Africa near the worldwide norm for liver cancer mortality. In Sub-Saharan Africa, liver cancer mortality is broadly in line with global averages, though the region's young demographic profile and high infectious disease burden shape the overall mortality landscape.
Sub-Saharan Africa faces the world's most acute health challenges, with the youngest population of any region, the highest burden of infectious diseases, and health systems constrained by limited financing and workforce shortages. Within Sub-Saharan Africa, significant variation exists. Sao Tome and Principe records the highest share at 5.9% of total deaths, while Zimbabwe has the lowest at 1.04%. This 4.8 percentage-point spread reflects differences in exposure, health system capacity, demographic structure, and risk factor prevalence across the region. Country-level pages provide detailed mortality breakdowns, time trends, and comparisons for each nation.
Hepatitis B vaccination — ideally with a birth dose — is the cornerstone of liver cancer prevention in endemic countries. Direct-acting antiviral therapy can cure over 95% of hepatitis C infections, halting liver fibrosis progression. Alcohol policy interventions (pricing, availability restrictions, advertising bans) reduce alcohol-attributable liver mortality. Addressing the NAFLD epidemic requires the same metabolic risk factor management strategies used for diabetes and cardiovascular disease: weight loss, physical activity, and dietary improvement. Screening of high-risk groups for hepatitis and liver fibrosis enables earlier intervention.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for liver cancer in Sub-Saharan Africa, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For liver cancer across Sub-Saharan Africa, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.